The time to sell was in the first six weeks after the REDUCE-IT results came out.
When this thing hit a market cap of $7 billion, I should have thought, "The pie in the sky upside is a double, and there's no floor under this given GIA possibilities and the patent exposure."
It would have been way easier to get a double from there on tech stocks than to take that risk.
Robin. sorry for your ( to date ) paper loss Some trading rules I force myself to stick to ....should you find yourself in that position again. I always " sell the news "...enough so that most of my initial investment is covered . The approval of the R-IT indication in Dec 2019 was a classic sell the news event .....followed by a classic technical sell signal that traders such as FFS and I follow. Stock opened higher and closed lower on very heavy volume ...on a major news day .
Second thing I do is force myself to reanalyze my position if the stock drops more then 20% from its recent high . Usually I will reduce my exposure further ...as in early 2020 ..despite being labeled a fudster by some still posting today . JL also warned of the risk in early 2020 ...as poster Zip recently mentioned.
The above is simple risk management , along with diversification ...hope that helps .
IMHO Vazkepa faces a major challenge in gaining reimbursement in the EU because of its 2b level of evidence rating . Vs say the new weight loss / heart failure drug thats now I believe a 1 a level of evidence rating . Given a choice the health depts will cover 1a drugs before 2b level drugs . How do you raise a 2 b drug to a 1 a drug ...more independent clinical trials ...even if only in select sub groups such as US secondary prevention patients revascularisation rates . Finally ..Statins plus Vascepa do not prevent getting Covid ...speaking from personal experience of just testing positive for Covid . Wife insists on a trip to the ER in the am plus a Paxlovid script . Yes Covid is still with us Hope you are doing well ( beyond your AMRN position } Kiwi